Our Portfolio

Afmedica

Afmedica, Inc. was founded to develop a sirolimus-impregnated polymer vascular 'wrap' to prevent the excess scarring that can occur inside blood vessels following vascular surgery and adhesions after other surgical procedures. Afmedica was sold to Angiotech Pharmaceuticals, Vancouver, BC, Canada.

Sierra Oncology

Sierra Oncology, Inc.is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) for the treatment of patients with cancer. Sierra Oncology was founded as ProNAi Therapeutics, Inc. and went public July 16, 2015. The name was changed to Sierra Oncology effective January 9, 2017 (NASDAQ: SRRA). For more information please visit sierraoncology.com/.

Armune

Armune® BioScience, Inc. develops and commercializes blood tests that leverage the warning signals produced by the bodys immune system in response to the onset of cancer.For more information please visit www.armune.com.

Mucimed

MuciMed, Inc. is focused on developing and commercializing mucin proteins for the treatment of gastrointestinal (GI) disease. For more information please contact Ronald J. Shebuski, PhD, President & CEO at 906-458-6212 or This email address is being protected from spambots. You need JavaScript enabled to view it..

Tetra

Tetra Discovery Partners is developing a platform of drug products to treat cognitive impairment. The Apjohn Group was not involved with founding Tetra, but advised in the formation of a special purpose investment entity to co-lead a $5 million Series A round of financing with the Grand Angels. Included in the full Series A investor list are Dolby Family Ventures, the Alzheimer's Drug Discovery Foundation, and other private investors. For more information please visit tetradiscovery.com.

Apjohn Group • 350 E. Michigan Ave., Suite 500 • Kalamazoo, Michigan 49007 • 269-349-8999